<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the causes and treatment of hyperphosphatemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the causes and treatment of hyperphosphatemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the causes and treatment of hyperphosphatemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason R Stubbs, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan S L Yu, MB, BChir
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phosphate is an inorganic molecule consisting of a central phosphorus atom and four oxygen atoms. In the steady state, the serum phosphate concentration is primarily determined by the ability of the kidneys to excrete dietary phosphate. The diagnostic approach to hyperphosphatemia involves elucidating why phosphate entry into the extracellular fluid exceeds the degree to which it can be excreted in order to maintain normal plasma levels.
        </p>
        <p>
         A broad overview of the causes and treatment of hyperphosphatemia is presented in this topic. Detailed discussions of renal osteodystrophy and the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) are found elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">
          "Management of hyperphosphatemia in adults with chronic kidney disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9791355">
         <span class="h1">
          CAUSES OF HYPERPHOSPHATEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal excretion is so efficient in normal subjects that balance can be maintained with only a minimal rise in serum phosphate concentration even if phosphorus intake is increased to as much as 4000 mg/day (130 mmol/day). Phosphorus intake above 4000 mg/day (130 mmol/day) causes only small elevations in serum phosphate concentrations as long as the intake is distributed over the course of the day. If, however, an acute phosphate load is given over several hours, transient hyperphosphatemia will ensue.
        </p>
        <p>
         The diagnostic approach to hyperphosphatemia involves elucidating why phosphate entry into the extracellular fluid exceeds the degree to which it can be excreted or why the renal threshold for phosphate excretion is increased above normal. There are four general circumstances in which this occurs (
         <a class="graphic graphic_table graphicRef89978" href="/z/d/graphic/89978.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute phosphate load
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute extracellular shift of phosphate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute or chronic kidney disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A primary increase in tubular phosphate reabsorption
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Acute phosphate load
         </span>
         <span class="headingEndMark">
          —
         </span>
         A phosphate load sufficient to overwhelm renal capacity for excretion can be derived from either endogenous or exogenous sources. Since phosphate is the major intracellular anion, any cause of marked tissue breakdown can lead to release of intracellular phosphate into the extracellular fluid. The ensuing hyperphosphatemia may then induce potentially symptomatic hypocalcemia due to calcium-phosphate precipitation in the tissues. Examples of marked tissue breakdown include tumor lysis syndrome, muscle necrosis (rhabdomyolysis), and, rarely, marked hemolysis or transfusion of stored blood.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Tumor lysis syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumor lysis syndrome is most often caused by cytotoxic therapy (but can occasionally occur spontaneously) in patients with a large burden of a tumor characterized by rapid cell turnover, such as lymphomas (particularly Burkitt lymphoma and non-Hodgkin lymphoma) and certain leukemias [
         <a href="#rid1">
          1
         </a>
         ]. In addition to release of phosphate, this syndrome is also associated with the release of potassium, purines (which can be metabolized to uric acid), and cell proteins (which can be metabolized to urea). Thus, hyperkalemia, hyperuricemia (which may lead to acute kidney injury [AKI]), and azotemia are other common metabolic complications [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">
          "Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Rhabdomyolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar considerations apply to rhabdomyolysis except that myoglobin is also released from the damaged cells [
         <a href="#rid4">
          4,5
         </a>
         ]. The severity of the hyperphosphatemia and hypocalcemia may be increased if heme pigment-induced AKI ensues. In these patients, resolution of the kidney injury can lead to hypercalcemia as the serum phosphate concentration falls and the tissue calcium-phosphate deposits are mobilized [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Exogenous phosphate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperphosphatemia from exogenous sources is most commonly induced by the ingestion of large amounts of phosphate-containing laxatives [
         <a href="#rid6">
          6-9
         </a>
         ]. Fleet's Phospho-Soda (which is no longer available over the counter), for example, contains 132 mg (4.25 mmol) of inorganic phosphate per mL. As a result, 20 mL taken over three to six hours can cause severe, even fatal, hyperphosphatemia and hypocalcemia. Less commonly, hyperphosphatemia has been reported in patients receiving high-dose
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         for the treatment of seizures [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In addition to absorption of the excess phosphate associated with phosphate-containing laxatives, volume contraction (due to diarrhea) and mild kidney function impairment (due to decreased kidney perfusion) may contribute to hyperphosphatemia in this setting. A review of the literature suggests that patients with underlying chronic kidney disease (CKD) are at particularly high risk for hyperphosphatemia due to phosphate-containing medications [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h4">
          Acute phosphate nephropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a number of reports describing acute or subacute kidney injury (called acute phosphate nephropathy or phosphate nephropathy) occurring after the ingestion of sodium-phosphate laxatives (solution or tablets) as bowel preparation for colonoscopy [
         <a href="#rid11">
          11-14
         </a>
         ]. This is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7218.html" rel="external">
          "Acute phosphate nephropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H539317872">
         <span class="h2">
          Acute extracellular shift of phosphate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Massive cellular shifts of phosphate out of the cells are a rare cause of hyperphosphatemia but has been documented with lactic acidosis and diabetic ketoacidosis (or severe hyperglycemia alone) [
         <a href="#rid15">
          15-17
         </a>
         ]. In addition to promoting a shift of phosphate out of cells, metabolic acidosis can diminish glycolysis and therefore cellular phosphate utilization, resulting in an increase in the serum phosphate.
        </p>
        <p>
         For unclear reasons, other forms of acidosis are less likely to be associated with hyperphosphatemia. In the case of lactic acidosis, concurrent tissue hypoxia and cell death is likely to further contribute to a decreased consumption and increased release of phosphate from cells. In the case of diabetic ketoacidosis, decreased cellular phosphate uptake due to insulin deficiency may contribute to the hyperphosphatemia. However, such patients are usually phosphate depleted, resulting from phosphaturia associated with the osmotic diuresis induced by hyperglycemia [
         <a href="#rid17">
          17
         </a>
         ]. The phosphate deficiency in these patients will typically be unmasked (leading to hypophosphatemia) by the administration of insulin. (See
         <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Serum phosphate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Acute or chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The filtered load of phosphorus is approximately 4 to 8 g/day (130 to 194 mmol/day). If, for example, the glomerular filtration rate (GFR) is 180 L/day (125 mL/min) and the phosphorus concentration is 4 mg/dL (1.3 mmol/L), then the filtered load will be 7.2 g/day. Only 5 to 20 percent of the filtered phosphorus is normally excreted, with most being reabsorbed in the proximal tubule [
         <a href="#rid18">
          18,19
         </a>
         ]. The normal physiologic regulation of renal phosphate excretion is described elsewhere in detail; briefly, the following factors are involved (see
         <a class="medical medical_review" href="/z/d/html/830.html" rel="external">
          "Hypophosphatemia: Causes of hypophosphatemia", section on 'Increased urinary excretion'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum phosphate concentration – Hyperphosphatemia can directly diminish proximal tubular phosphate reabsorption via suppression of sodium-phosphate cotransporters in the luminal membrane that mediate reabsorption of filtered phosphate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parathyroid hormone – Parathyroid hormone (PTH) increases phosphate excretion by diminishing activity of sodium-phosphate cotransporters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Phosphatonins – Similar to PTH, phosphatonins such as fibroblast growth factor 23 (FGF23) and secreted frizzled related protein-4 (sFRP-4) enhance urinary phosphate excretion by suppressing the luminal expression of sodium-phosphate cotransporters.
        </p>
        <p>
        </p>
        <p>
         An acute or chronic reduction in GFR will initially diminish phosphate filtration and excretion. Nevertheless, phosphate balance can initially be maintained in such patients by decreasing proximal phosphate reabsorption under the influence of increased secretion of PTH and FGF23. Once the GFR falls below 20 to 25 mL/min, however, phosphate reabsorption is thought to be maximally suppressed, and urinary excretion may no longer keep pace with phosphate intake. At this point, hyperphosphatemia occurs, increasing the filtered load and reestablishing phosphate balance. (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Increased tubular reabsorption of phosphate
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to a reduction in GFR, phosphate excretion can also be diminished by an increase in proximal phosphate reabsorption. This usually occurs in patients with otherwise normal kidney function who have one of the following conditions:
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Hypoparathyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Either deficient PTH secretion or renal resistance to PTH (pseudohypoparathyroidism) results in increased phosphate reabsorption and leads to hyperphosphatemia. These patients also have hypocalcemia due to reduced bone resorption and urinary calcium losses. (See
         <a class="medical medical_review" href="/z/d/html/840.html" rel="external">
          "Etiology of hypocalcemia in adults"
         </a>
         .)
        </p>
        <p>
         Treatment with calcium and vitamin D (or
         <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">
          calcitriol
         </a>
         [1,25-dihydroxyvitamin D, the most active metabolite of vitamin D]) lowers the serum phosphate concentration, although not always to the normal range. How this occurs is not clear, although two potential mechanisms include the following: calcium and vitamin D therapy increase the serum calcium concentration, which may directly diminish phosphate transport in the proximal tubule; calcitriol stimulates FGF23 production by bone, which could lead to a suppression of phosphate reabsorption by the proximal tubule.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Acromegaly
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperphosphatemia occurs in some patients with acromegaly. It is presumably due to direct stimulation of phosphate reabsorption by growth hormones or insulin-like growth factor I [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Bisphosphonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bisphosphonates, primarily
         <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">
          etidronate
         </a>
         , can cause mild hyperphosphatemia [
         <a href="#rid21">
          21,22
         </a>
         ]. This effect is mediated in part by direct stimulation of renal phosphate reabsorption [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2967225390">
         <span class="h3">
          FGFR inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of cancer patients treated with fibroblast growth factor receptor (FGFR) inhibitors, such as
         <a class="drug drug_general" data-topicid="121054" href="/z/d/drug information/121054.html" rel="external">
          erdafitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">
          infigratinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">
          pemigatinib
         </a>
         , develop hyperphosphatemia [
         <a href="#rid23">
          23,24
         </a>
         ]. This class effect is due to inhibition of fibroblast growth factor 23 (FGF23) signaling. FGF23 normally maintains systemic phosphate balance by stimulating urinary phosphate excretion; thus, blockade of FGF23 signaling enhances phosphate reabsorption in the proximal tubule, potentially resulting in hyperphosphatemia. This is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">
          "Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'FGFR inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Vitamin D toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperphosphatemia may be associated with vitamin D toxicity. Vitamin D increases intestinal phosphate and calcium absorption, and the rise in serum calcium concentration diminishes urinary phosphate excretion, both by inhibiting PTH secretion and, in many cases, by impairing kidney function (in part due to direct renal vasoconstriction).
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Familial tumoral calcinosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial tumoral calcinosis is a rare autosomal recessive disorder characterized by hyperphosphatemia due to an increase in proximal tubular phosphate reabsorption, often in association with increased serum
         <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">
          calcitriol
         </a>
         concentrations [
         <a href="#rid25">
          25
         </a>
         ]. The underlying defect that was first described was a mutation in the GALNT3 gene, which encodes a glycosyltransferase that is thought to prevent the degradation of FGF23 [
         <a href="#rid26">
          26,27
         </a>
         ]. Gene mutations in FGF23 and Klotho (the FGF23 coreceptor) have also been described [
         <a href="#rid28">
          28-31
         </a>
         ]. It is postulated that inactivating mutations in either the GALNT3 or FGF23 genes could lead to deficiency of circulating intact FGF23, which is a promoter of renal phosphate excretion [
         <a href="#rid26">
          26
         </a>
         ]. In addition, FGF23 requires Klotho to bind to its receptor; therefore, a deficiency in Klotho could lead to a state of FGF23 end-organ resistance [
         <a href="#rid32">
          32,33
         </a>
         ]. FGF23 and Klotho are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Fibroblast growth factor 23'
         </a>
         .)
        </p>
        <p>
         Familial tumoral calcinosis appears to be the mirror image of X-linked and autosomal dominant hypophosphatemic rickets in which increased activity of FGF23 causes a primary increase in renal phosphate excretion. The gold standard for diagnosis of familial tumoral calcinosis is genetic sequencing from whole blood samples. Detailed information regarding genetic testing for this disorder can be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fconditions%2FC1876187%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trz%2FHgqPF5O7b%2FosjhMokBiXf1%2BuWcZggqA2tojQTwSxTQ%3D%3D&amp;TOPIC_ID=828" target="_blank">
          here
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">
          "Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"
         </a>
         .)
        </p>
        <p>
         Serum calcium and PTH concentrations are typically within the normal range in patients with familial tumoral calcinosis. The tendency of phosphate to complex with calcium and cause hypocalcemia appears to be counterbalanced by increased production of 1,25-dihyroxyvitamin D and perhaps hyperphosphatemia-induced stimulation of calcium reabsorption in the distal nephron. The combination of hyperphosphatemia and normocalcemia results in a high calcium-phosphate product and calcium-phosphate deposition in the skin and subcutaneous tissues [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Lowering the serum phosphate concentration by dietary restriction and phosphate binders, which impair intestinal phosphate absorption, often results in resolution of these deposits [
         <a href="#rid25">
          25,35
         </a>
         ]. If this is ineffective, increasing urinary phosphate excretion by the chronic administration of
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         may be beneficial [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Pseudohyperphosphatemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spurious hyperphosphatemia due to interference with analytical methods may rarely occur in patients with hyperglobulinemia (any type of immunoglobulin in excess quantity), hyperlipidemia, hemolysis, and hyperbilirubinemia [
         <a href="#rid37">
          37-40
         </a>
         ]. Among these conditions, the most common is hyperglobulinemia due to multiple myeloma, Waldenström macroglobulinemia, or monoclonal gammopathy [
         <a href="#rid37">
          37,38
         </a>
         ]. Extreme pseudohyperphosphatemia due to therapy with high-dose
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         has also been reported [
         <a href="#rid41">
          41
         </a>
         ], as has spurious hyperphosphatemia due to sample contamination with recombinant tissue plasminogen activator or heparin [
         <a href="#rid42">
          42,43
         </a>
         ]. Phosphate can be determined accurately by use of alternative analysis methods [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          TREATMENT OF HYPERPHOSPHATEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to therapy differs in acute and chronic hyperphosphatemia. Acute severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. The hyperphosphatemia usually resolves within 6 to 12 hours if kidney function is intact. If kidney function is intact, phosphate excretion can be increased by
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion, although this can further reduce the serum calcium concentration by dilution. Hemodialysis may be indicated in patients with symptomatic hypocalcemia, particularly if kidney function is impaired.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Chronic hyperphosphatemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic hyperphosphatemia requiring therapy occurs in patients with chronic kidney disease (CKD) and familial tumoral calcinosis. Treatment consists of diminishing intestinal phosphate absorption by a low-phosphate diet and phosphate binders. (See
         <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">
          "Management of hyperphosphatemia in adults with chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H333181443">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of hyperphosphatemia
         </strong>
         – Hyperphosphatemia results when phosphate entry into the extracellular fluid exceeds the rate at which it can be excreted. There are four general circumstances in which this occurs (
         <a class="graphic graphic_table graphicRef89978" href="/z/d/graphic/89978.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Causes of hyperphosphatemia'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute phosphate load
         </strong>
         – Increased extracellular phosphate from endogenous sources occurs in tumor lysis syndrome, muscle necrosis (rhabdomyolysis), and, rarely, marked hemolysis or transfusion of stored blood. An acute exogenous phosphate load may result from the ingestion of a large amount of a phosphate-containing laxative. Volume contraction (due to diarrhea) and mild kidney function impairment (due to decreased kidney perfusion) may contribute to hyperphosphatemia in this setting. (See
         <a class="local">
          'Acute phosphate load'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute extracellular shift of phosphate
         </strong>
         –
         <strong>
         </strong>
         Lactic acidosis and diabetic ketoacidosis (or severe hyperglycemia alone) may also cause increased mobilization of intracellular phosphate into the extracellular fluid. (See
         <a class="local">
          'Acute extracellular shift of phosphate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute or chronic kidney disease
         </strong>
         – Acute or chronic kidney disease is a common cause of diminished phosphate excretion. Urinary excretion may not keep pace with phosphate intake when the glomerular filtration rate (GFR) falls below 20 to 25 mL/min. (See
         <a class="local">
          'Acute or chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increased tubular resorption of phosphate
         </strong>
         – Increased proximal phosphate reabsorption occurs in patients with hypoparathyroidism or acromegaly, during treatment with bisphosphonates, fibroblast growth factor receptor (FGFR) inhibitors, or vitamin D, and due to a heritable condition called familial tumoral calcinosis. (See
         <a class="local">
          'Increased tubular reabsorption of phosphate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pseudohyperphosphatemia
         </strong>
         – Pseudohyperphosphatemia may rarely be caused by interference with analytical methods in patients with hyperglobulinemia, hyperlipidemia, hemolysis, and hyperbilirubinemia and has been reported with high-dose
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         , recombinant tissue plasminogen activator, and heparin. (See
         <a class="local">
          'Pseudohyperphosphatemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. Phosphate excretion can be increased by
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion if kidney function is intact. Hemodialysis may be indicated in patients with symptomatic hypocalcemia, particularly if kidney function is impaired. (See
         <a class="local">
          'Treatment of hyperphosphatemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chronic hyperphosphatemia occurs in patients with CKD and familial tumoral calcinosis. Treatment consists of diminishing intestinal phosphate absorption by a low-phosphate diet and phosphate binders. (See
         <a class="local">
          'Chronic hyperphosphatemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1065343">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Zalman S Agus, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol. N Engl J Med 1981; 305:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997; 29:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda in a patient with colonic ileus. Am J Gastroenterol 1993; 88:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curran MP, Plosker GL. Oral sodium phosphate solution: a review of its use as a colorectal cleanser. Drugs 2004; 64:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBryde KD, Wilcox J, Kher KK. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 2005; 20:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003; 349:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16:3389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonlusen G, Akgun H, Ertan A, et al. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006; 130:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor LR, Klein KL, Bethune JE. Hyperphosphatemia in lactic acidosis. N Engl J Med 1977; 297:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternbach GL, Varon J. Severe hyperphosphatemia associated with hemorrhagic shock. Am J Emerg Med 1992; 10:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murer H, Lötscher M, Kaissling B, et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int 1996; 49:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quigley R, Baum M. Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 1991; 88:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 1975; 49:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Challa A, Noorwali AA, Bevington A, Russell RG. Cellular phosphate metabolism in patients receiving bisphosphonate therapy. Bone 1986; 7:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; 381:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyou Y, Grivas P, Rosenberg JE, et al. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol 2020; 78:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitnick PD, Goldfarb S, Slatopolsky E, et al. Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med 1980; 92:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007; 22:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chefetz I, Heller R, Galli-Tsinopoulou A, et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araya K, Fukumoto S, Backenroth R, et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:5523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117:2684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancovitch A, Hershkovitz D, Indelman M, et al. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J Bone Miner Metab 2011; 29:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavin RE, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol 1993; 17:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mozaffarian G, Lafferty FW, Pearson OH. Treatment of tumoral calcinosis with phosphorus deprivation. Ann Intern Med 1972; 77:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaguchi T, Sugimoto T, Imai Y, et al. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone 1995; 16:247S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larner AJ. Pseudohyperphosphatemia. Clin Biochem 1995; 28:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler SG, Laidlaw SA, Lubran MM, Kopple JD. Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 1988; 11:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leehey DJ, Daugirdas JT, Ing TS, Reid RW. Spurious hyperphosphatemia due to hyperlipidemia. Arch Intern Med 1985; 145:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randall AG, Garcia-Webb P, Beilby JP. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem 1990; 27 ( Pt 4):345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane JW, Rehak NN, Hortin GL, et al. Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta 2008; 387:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiller B, Virk B, Blair M, et al. Spurious hyperphosphatemia in patients on hemodialysis with catheters. Am J Kidney Dis 2008; 52:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball CL, Tobler K, Ross BC, et al. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med 2004; 42:107.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 828 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6894477" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8430709" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8321927" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Tumor lysis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4423658" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nontraumatic rhabdomyolysis and acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6894630" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9002537" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8503390" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fatal hyperphosphatemia following Fleet Phospo-Soda in a patient with colonic ileus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12695271" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15257632" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Oral sodium phosphate solution: a review of its use as a colorectal cleanser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965770" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12954755" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute phosphate nephropathy and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15188133" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192415" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390223" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/408683" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hyperphosphatemia in lactic acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1616521" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Severe hyperphosphatemia associated with hemorrhagic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3933341" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Dynamic changes in serum phosphorus levels in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1498272" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8743494" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1864951" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/807449" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3094565" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cellular phosphate metabolism in patients receiving bisphosphonate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31340094" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32847703" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6244768" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Calcium and phosphate metabolism in tumoral calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15133511" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17129170" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16151858" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16030159" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17710231" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21347749" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436388" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Regulation of fibroblast growth factor-23 signaling by klotho.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17086194" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Klotho converts canonical FGF receptor into a specific receptor for FGF23.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8338191" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4538804" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of tumoral calcinosis with phosphorus deprivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7626311" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8521592" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pseudohyperphosphatemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3125742" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3985738" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Spurious hyperphosphatemia due to hyperlipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403233" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17936740" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18534730" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Spurious hyperphosphatemia in patients on hemodialysis with catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15061391" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
